← Trials/Trial dossier/NCT01779362
RISE Adult
CompletedPhase 3Results postedRISE Adult Medication Study
Restoring Insulin Secretion Adult Medication Study
Lead sponsor
Asset
Liraglutide
Subcutaneous · GLP-1 agonist
Listed sites
4
Recruiting sites
—
Enrollment
267
actual
Study population
Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes
Key I/E criteria
•BMI ≥25•HbA1c ≤7%
Primary endpoints
•SS-cell Response•HOMA-IR (insulin sensitivity)
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Fasting plasma glucose 95-125 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus HbA1c ≤7.0%. There is no upper limit for the 2-hour glucose on OGTT.
2. Age 20-65 years
3. Body mass index (BMI) ≥25 kg/m2 but ≤50 kg/m2
4. Self-reported diabetes <1 year in duration
5. Drug naïve (no prior to oral glucose lowering agent(s), insulin or other injectable glucose lowering agents)
Exclusion criteria
1. Underlying disease likely to limit life span and/or increase risk of intervention or an underlying condition that is likely to limit ability to participate in outcomes assessment
2. An underlying disease that affects glucose metabolism other than type 2 diabetes
3. Taking medications that affect glucose metabolism, or has an underlying condition that is likely to require such medications
4. Active infections
5. Renal disease (serum creatinine >1.4 mg/dl for men; >1.3 mg/dl for women) or serum potassium abnormality (<3.4 or >5.5 mmol/l)
6. Anemia (hemoglobin <11 g/dl in women, <12 g/dl in men) or known coagulopathy
7. Cardiovascular disease, including uncontrolled hypertension. Participants must be able to safely tolerate administration of intravenous fluids required during clamp studies.
8. History of conditions that may be precipitated or exacerbated by a study drug:
1. Pancreatitis
2. Serum alanine transaminase (ALT) more than 3 times the upper limit of normal
3. Excessive alcohol intake
4. Suboptimally treated thyroid disease
5. Medullary carcinoma of the thyroid or MEN-2 (in participant or a family history)
6. Hypertriglyceridemia (>400 mg/dl despite treatment)
9. Conditions or behaviors likely to affect the conduct of the RISE Study
1. Unable or unwilling to give informed consent
2. Unable to adequately communicate with clinic staff
3. Another household member is a participant or staff member in RISE
4. Current, recent or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in RISE
5. Weight loss of >5% in past three months for any reason other than post-partum weight loss. Participants taking weight loss drugs or using preparations taken for intended weight loss are excluded.
6. Likely to move away from participating clinics in next two years
7. Women of childbearing potential who are unwilling to use adequate contraception
8. Current (or anticipated) pregnancy and lactation.
9. Major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of RISE
10. Additional conditions may serve as criteria for exclusion at the discretion of the local site.
Endpoints (8)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Glycemic / diabetes
8 endpointsß-cell Response Measured by Hyperglycemic Clamp
Time frame:3-months after medication washout (Month 15)
descriptive
Posted result
| Group | Value (geometric_mean), nmol/L | 95% CI |
|---|---|---|
| Metformin AloneSteady State C-peptide | 3.65 | 1.94 – 6.87 |
| ACPRmax | 4.61 | 2.00 – 10.66 |
| Glargine Followed by MetforminSteady State C-peptide | 3.58 | 1.68 – 8.33 |
| ACPRmax | 4.32 | 1.58 – 11.80 |
| PlaceboSteady State C-peptide | 3.60 | 1.72 – 7.53 |
| ACPRmax | 4.45 | 1.56 – 12.71 |
| Liraglutide + MetforminSteady State C-peptide | 3.73 | 1.87 – 7.44 |
| ACPRmax | 4.58 | 2.21 – 9.48 |
Insulin Sensitivity, M/I
Time frame:3-months after a medication washout
HOMA-IR (insulin sensitivity)
descriptive, improvement
Posted result
| Group | Value (geometric_mean), x 10-5 mmol/kg/min per pmol/L | 95% CI |
|---|---|---|
| Metformin Alone | 3.53 | 0.67 – 18.49 |
| Glargine Followed by Metformin | 3.38 | 0.61 – 18.84 |
| Placebo | 3.63 | 0.95 – 13.84 |
| Liraglutide + Metformin | 3.49 | 0.90 – 13.54 |
ß-cell Response Measured by Hyperglycemic Clamp
Time frame:3-months after medication washout (Month 15)
descriptive
Insulin Sensitivity, M/I
Time frame:3-months after a medication washout
HOMA-IR (insulin sensitivity)
change from baseline, improvement
ACPRg
Time frame:3-months after a medication washout
descriptive
Posted result
| Group | Value (geometric_mean), nmol/L | 95% CI |
|---|---|---|
| Metformin Alone | 1.68 | 0.84 – 3.34 |
| Glargine Followed by Metformin | 1.68 | 0.91 – 3.09 |
| Placebo | 1.68 | 0.86 – 3.26 |
| Liraglutide + Metformin | 1.68 | 0.99 – 2.83 |
ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12
Time frame:Secondary analysis was on all participants with a Month 12 visit.
descriptive
Posted result
| Group | Value (geometric_mean), nmol/L | 95% CI |
|---|---|---|
| Metformin AloneACRPg | 1.93 | 1.09 – 3.40 |
| Steady State C-peptide | 11.7 | 5.6 – 24.3 |
| ACRPmax | 13.4 | 5.9 – 30.7 |
| Glargine Followed by MetforminACRPg | 1.88 | 1.06 – 3.22 |
| Steady State C-peptide | 11.6 | 5.6 – 24.3 |
| ACRPmax | 14.1 | 5.8 – 34.3 |
| PlaceboACRPg | 1.69 | 0.89 – 3.22 |
| Steady State C-peptide | 10.8 | 5.1 – 22.7 |
| ACRPmax | 13.6 | 5.1 – 36.1 |
| Liraglutide + MetforminACRPg | 2.68 | 1.28 – 5.60 |
| Steady State C-peptide | 21.2 | 9.3 – 48.3 |
| ACRPmax | 10.1 | 3.5 – 28.5 |
Analyses were completed on a log scale and re-exponentiated for display.
ACPRg
Time frame:3-months after a medication washout
change from baseline, improvement
ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12
Time frame:Secondary analysis was on all participants with a Month 12 visit.
descriptive
Publications (15)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- The Journal of clinical endocrinology and metabolism2023 Sep 18PMID36938582doi:10.1210/clinem/dgad135via clinicaltrials gov reference derived + pubmed nct search
- Obesity (Silver Spring, Md.)2022 Aug (month)PMID35894078doi:10.1002/oby.23475via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2021 Sep (month)PMID34135015doi:10.2337/dc21-0461via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2021 Sep (month)PMID34131048doi:10.2337/dc21-0027via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2021 Sep (month)PMID34131047doi:10.2337/dc21-0460via clinicaltrials gov reference derived + pubmed nct search
- Diabetes research and clinical practice2021 Aug (month)PMID34274407doi:10.1016/j.diabres.2021.108948via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2021 Mar (month)PMID33436401doi:10.2337/dc20-2134via clinicaltrials gov reference derived + pubmed nct search
- The Cochrane database of systematic reviews2020 Jun 5PMID32501595doi:10.1002/14651858.CD012906.pub2via clinicaltrials gov reference derived + pubmed nct search
- Pediatric diabetes2019 Nov (month)PMID31301210doi:10.1111/pedi.12883via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2019 Sep (month)PMID31178434doi:10.2337/dc19-0556via clinicaltrials gov reference derived + pubmed nct search
- Diabetes2019 Aug (month)PMID31178433doi:10.2337/db19-0299via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2018 Aug (month)PMID29941497doi:10.2337/dc18-0244via clinicaltrials gov reference derived + pubmed nct search
- Diabetes care2018 Aug (month)PMID29941498doi:10.2337/dc18-0243via clinicaltrials gov reference derived + pubmed nct search
- Diabetes, obesity & metabolism2018 Jan (month)PMID28493515doi:10.1111/dom.13005via CT.gov background + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.